
Expanding Access to CAR T, Bispecific Therapies Requires System Changes: Peter Forsberg, MD
Peter Forsberg, MD, discusses why health systems must adapt to expand equitable access to CAR T-cell and bispecific therapies.
Captions are auto-generated.
Chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies are moving into earlier lines of treatment for patients who have
“As the trials that lead to these approvals demonstrate really dramatic improvements in efficacy, it's really a necessity that we find improved ways to get access to these treatments to more patients,” he said.
Forsberg emphasized that health systems haven’t been fully operationalized to deliver these treatments on such a scale, and clinicians are working to find ways to expand access to treatments such as CAR T-cell therapy and bispecific T-cell engagers, for example.
“But where there is still a need for engagement for building structures and approaches to managing new toxicities, such as cytokine release syndrome, which is just outside of the new toxicities, there is a classical scope for a lot of systems,” Forsberg said. “It's a work in progress, but it is one that I think everybody understands the necessity of.”
However, there is no “one-size-fits-all” strategy to help health institutions implement or broaden access to these therapies, he emphasized. Each health institution has its own system and may require different measures across higher-level engagement, involving stakeholders and even community oncologists at the clinic level.
“I do think with how effective our new immunotherapeutic options in particular are, thinking about what system-level improvements need to be made to allow equity, and sustainability is key because I do think that the deep work that might require it has sometimes been lacking,” Forsberg said.




